For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Meso momentum - April deadline for co-design of organisations to replace PHOs
Meso momentum - April deadline for co-design of organisations to replace PHOs

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 4 March 2024.
From Barbara: The deadline has well come and gone, and the report was apparently sitting on the desk of commissioner Lester Levy at the end of 2024. Here Bryan Betty of General Practice NZ considers what might be coming in the way of meso level organisations
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.